Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial

Future Oncol. 2014 Nov;10(14):2141-7. doi: 10.2217/fon.14.144.

Abstract

Background: A multi-institutional Phase II trial was initiated in 2005 to test the combination gemcitabine and capecitabine in patients with thymic epithelial malignancies (TETs).

Patients & methods: Patients with histologic confirmation of TET diagnosis by central review who had received >1 systemic chemotherapy treatment were included. Patients received oral capecitabine (650 mg/mq twice daily on days 1-14) and intravenous gemcitabine (1000 mg/mq on days 1 and 8 every 3 weeks).

Results: Of the 30 patients included (18 men, 12 women; median age: 57 years, range: 48-61 years), the majority (73%) had thymoma, and the remaining thymic carcinoma. Eight patients developed grade 3-4 neutropenia. A total of 12 patients had a response. Median progression-free survival was 11 months (range: 6.5-16.5).

Conclusion: Capecitabine and gemcitabine is highly active in TETs.

Keywords: capecitabine; gemcitabine; thymic epithelial tumors; thymomas.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Capecitabine
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial / diagnosis
  • Neoplasms, Glandular and Epithelial / drug therapy*
  • Neoplasms, Glandular and Epithelial / mortality
  • Positron-Emission Tomography
  • Retreatment
  • Thymus Neoplasms / diagnosis
  • Thymus Neoplasms / drug therapy*
  • Thymus Neoplasms / mortality
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Deoxycytidine
  • Capecitabine
  • gemcitabine
  • Fluorouracil

Supplementary concepts

  • Thymic epithelial tumor